Kwality Pharma Appoints Bhavesh Mahajan as Director

Kwality Pharmaceuticals Ltd appoints CA Bhavesh Mahajan as Additional Independent Director for 5-year term from January 28, 2026 to January 27, 2031, subject to shareholder approval.

Kwality Pharma Appoints New Independent Director

Kwality Pharmaceuticals Limited has appointed Dr. PreetMohinder Singh Bedi as Additional Independent Director for a five-year term from January 1, 2026, to December 31, 2030.

Kwality Pharmaceuticals Reports 32% Revenue Growth in H1 FY26

Kwality Pharmaceuticals Limited reported consolidated revenue of ₹224 crore in H1 FY26, representing 32% year-on-year growth from ₹170 crore in H1 FY25. EBITDA increased 35% to ₹50 crore from ₹37 crore, with margins improving to 22.5% from 22.0%. Net profit rose to ₹26 crore from ₹17 crore in the previous year. The company accelerated R&D initiatives with multiple Bioequivalence and clinical trial programs across injectables and oral solid dosage segments. Capital expenditure for Biologics, Oncology, and Hormone manufacturing facilities is being funded through internal accruals. The company generated cash surplus of approximately ₹30 crore during the quarter and received multiple new product registrations. Management projects Q3 FY26 revenue of around ₹140 crore and remains confident of exceeding the ₹500 crore revenue target for the full year.

Kwality Pharmaceuticals Reports 66% Jump in Net Profit for Q2

Kwality Pharmaceuticals reported net profit of 141 million rupees for Q2, compared to 85 million rupees in the same period last year. The company's revenue increased to 1.11 billion rupees from 900 million rupees year-over-year.

Kwalitypharmaceuticals Completes EU-GMP Audit with No Major Observations

Kwalitypharmaceuticals Limited successfully completed a European Union Good Manufacturing Practices (EU-GMP) audit at its Amritsar manufacturing facilities, covering both General and Beta-Lactam units. The audit concluded with no major observations. The company now operates four EU-approved facilities: General, Beta-Lactam, Cephalosporin, and Oncology units. The successful audit strengthens the company's position as a pharmaceutical manufacturer across various therapeutic areas and dosage forms, and enables expansion into regulated international markets.